Yarrow
New York · Founded 2021
About Yarrow
Yarrow is developing a first-in-class antibody targeting TSHR for the treatment of Graves’ disease and thyroid eye disease.
Company Facts
- Founded: 2021
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Total funding: $200.0M
- Last round: Series Unknown (Dec 2025)
- Website: https://www.yarrowbioscience.com
- Phone: [email protected]
Industries & Categories
Business Intelligence, Health Care, Medical
Canonical: https://fsome.com/organization/yarrow-122330 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.